Aneurysm Subarachnoid haemorrhage/hemorrhage Tranexamic acid, Cyklokapron Acetylsalicylic acid, Aspirin Aneurysma Subarachnoidale bloeding Tranexaminezuur Acetylsalicylzuur, Aspirine
Conditions
Interventions
1. Group one: placebo administered intravenous in ten minutes, every four hours until four to eight hours preceding planned intervention followed by placebo every 24 hours until two weeks after aneury
2. Group two: 1 gram TA administrated intravenous in ten minutes, followed by a same dose every four hours until four to eight hours preceding planned intervention. In case of endovascular treatment,
Sponsors
Germans, M.R.
Coert, B.A.
Eligibility
Inclusion criteria
Inclusion criteria: 1. Aneurysmatic SAH less than 48 hours ago; 2. Age 18 years and older; 3. Informed consent.
Exclusion criteria
Exclusion criteria: 1. Presence of deep vein thrombosis; 2. History of blood coagulation disorder; 3. Use of antiplatelet or anticoagulation medication during haemorrhage; 4. Immediate neurosurgical intervention necessary (with the exception of ventricular drainage); 5. Contraindication for use of aspirin; 6. Pregnancy; 7. Thrombocytopenia (150 mmol/L) or liver failure (AST > 150 U/l or ALT > 150 U/l or AF > 150 U/l or ã-GT > 150 U/l); 9. Imminent death within 24 hours.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Modified Rankin Scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. In hospital possible or definite rebleed and interval with first haemorrhage; 2. Rebleed during endovascular or surgical treatment; 3. Thromboembolic events during endovascular treatment; 4. (Micro)infarctions on MR-imaging after treatment and after 6 months; 5. Hemorrhagic complications (intra and extracranial); 6. Extracranial thrombosis; 7. Treatment for hydrocephalus (lumbar puncture, lumbar or ventricular drainage); 8. Hemorrhagic complications with neurological deficit after placement of an extraventricular drain. | — |
Contacts
Public ContactM.R. Germans
Outcome results
None listed